menu

CME: New Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting

New Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting
RestartResume
Discover new treatment optimization for diabetic macular edema and diabetic retinopathy based on the data presented at the 2018 AAO annual meeting.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Presented by the Johns Hopkins University School of Medicine.

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

    Recent data, including those presented at the 2018 American Academy of Ophthalmology annual meeting, regarding the use of intravitreal anti-VEGF agents in patients with diabetic macular edema (DME) and diabetic retinopathy (DR), have the potential to shift treatment strategies by offering a therapy option that may prevent progression in earlier stages of disease. However, as ongoing research continues to evolve, it can be challenging for ophthalmologists and retina specialists to remain up-to-date on these findings and interpret their impact on patient management. This activity will not only provide an overview of the most current data on anti-VEGF treatments in patients with DR and DME, it will also evaluate potential clinical implications that can assist practicing clinicians in translating the results of this research into real-world patient care.

  • Target Audience

    This educational initiative is intended for comprehensive ophthalmologists and retina specialists, as well as other healthcare providers that manage patients with diabetic retinopathy and diabetic macular edema. No prerequisites required.

  • Learning Objectives

    After participating in this activity, the participant will demonstrate the ability to:

    • EVALUATE the most recent data supporting the use of anti-VEGF agents to mitigate or reverse the progression of diabetic retinopathy.
    • ASSESS up-to-date evidence evaluating individualized anti-VEGF agent selection and dosing strategies for DME.
    • RECOGNIZE the results for recent trials evaluating anti-VEGF agent monotherapy and steroid combination therapy for chronic/persistent DME.
    • UTILIZE evidence-based data to develop treatment plans that appropriately incorporate ant-VEGF treatments for DR and DME.

    The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

  • CME Information

    Accreditation Statement — The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement — The Johns Hopkins University School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    After reviewing this online activity, participants may receive a certificate by receiving a score of 70% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.

    The estimated time to complete this activity: 30 minutes.

    Release date: December 21, 2018

    Expiration date: December 21, 2019

  • Participating Faculty

    J. Fernando Arevalo, MD, FACS (Chair)
    Edmund F. and Virginia B. Ball Professor of Ophthalmology
    The Wilmer Eye Institute
    Johns Hopkins University School of Medicine
    Baltimore, Maryland

    Quan Dong Nguyen, MD, MSc, FAAO
    Professor of Ophthalmology
    Byers Eye Institute
    Stanford University School of Medicine
    Palo Alto, California

  • Disclosure Policies

    Policy on Speaker and Provider Disclosure
    It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.

    Full Disclosure Policy Affecting CME Activities
    As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. The following relationships have been reported for this activity:

    Planner Disclosures
    Dr. Arevalo reports receiving grants/research support from Topcon Medical Systems, Inc.; serving as a consultant for Allergan, Inc., Bayer AG, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Mallinckrodt Pharmaceuticals, and Turing Pharmaceuticals, LLC; receiving lecture fees from D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.; and receiving royalties from Springer SBM LLC.

    Participating Faculty Disclosures
    Dr. Nguyen reports serving as a principal investigator for and on the scientific advisory board for Genentech, Inc., Gilead Sciences, Inc, and Regeneron Pharmaceuticals, Inc.

    No other individual with the opportunity to affect this educational content has indicated any financial interests or relationships with a commercial entity.

    Note:  Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

    Off-Label Product Discussion
    No faculty member has indicated that he/she will reference unlabeled/unapproved uses of drugs or products.

  • Disclaimer

    The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own.  This enduring material is produced for educational purposes only.  Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach.  Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

  • Confidentiality Disclaimer for CME Activity Participants

    I certify that I am participating in a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

    I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations").   Protected health information is information about a person's health or treatment that identifies the person. 

    I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.  I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc), in any electronic messaging program or through any portable electronic device  

    I  understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this  Confidentiality  Pledge or under any of the Hopkins policies  and procedures  and  applicable  laws  and  regulations  related  to  confidentiality.    The contact information   is:       Johns   Hopkins   Privacy   Officer,   telephone:   410-735-6509,    e-mail: HIPAA@jhmi.edu.

    “The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”

    For CME Questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu. For CME Certificates, please call 410-502-9634.

    Johns Hopkins University School of Medicine Office of Continuing Medical Education
    Turner 20/720 Rutland Avenue
    Baltimore, Maryland
    21205-2195

    Reviewed & Approved by:
    General Counsel, Johns Hopkins Medicine (4/1/03)
    (Updated 4/09 and 3/14)

  • Activity

    Instructions
    The following is an interactive enduring activity that’s designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the activity, and a CME postassessment and evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the activity.

    Preassessment
    New Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting
    J. Fernando Arevalo, MD, FACS, and Quan Dong Nguyen, MD, MSc, FAAO
    Postassessment and evaluation

    This activity was developed in collaboration with ASiM. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.